Sweden's Stille Q4 net sales rise 8.5% yr/yr

Stille AB

12/02/2026 07:14

Overview

Swedish surgical instruments maker's Q4 net sales rose 8.5% yr/yr

Company's gross margin decreased to 51.1% from 58.4%

EBITDA before non-recurring items fell to MSEK 38.1 from MSEK 46.3

Outlook

Stille expects solid growth in 2026 driven by strong order intake and operational improvements

Company sees improved supply chain conditions supporting long-term value creation

Result Drivers

PRODUCT PHASE-OUT - Co's Q4 results negatively impacted by phase-out of non-strategic surgical instruments

CURRENCY EFFECT - Negative currency effect reduced net sales by MSEK 9.9

SUPPLY CHAIN IMPROVEMENT - Improved supply chain reduced delivery times, per CEO Ulrik Berthelsen

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
SEK 174.90 mln
SEK 154.50 mln (2 Analysts)
Q4 Adjusted EBITDA
SEK 38.10 mln
Q4 Adjusted EBIT
SEK 28.50 mln
Q4 EBIT
SEK 28.50 mln
Q4 EBITDA
SEK 38.10 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Stille AB is SEK239.00, about 60.9% above its February 11 closing price of SEK148.50

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nMFNvnnt6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)